Loading…
Loading…
IRVINE, CA / ACCESSWIRE / January 23, 2024 / HippoFi's (OTC PINK:ORHB) biotechnology business PUR Biologics, proudly announces Scott Bauccio as its new Head of Sales. Utilizing his 20 years of sales management and his extensive network of industry- leading sales professionals, Bauccio is expanding the company's sales and distribution channels; already securing two new products: PURamnio (selling now) and PURpeptide (launching within 30 days).
HippoFi's wholly owned subsidiary, PUR Biologics breaks into the international market. IRVINE, CA / ACCESSWIRE / December 11, 2023 / HippoFi's (OTC PINK:ORHB) biotechnology business PUR Biologics, began selling and shipping products for international use, closing out a phenomenal year of accomplishments.
Expanding our reach in 2024, HippoFi and PUR Biologics are setting new standards in innovative spine care solutions . IRVINE, CA / ACCESSWIRE / December 5, 2023 / (OTC PINK:ORHB) HippoFi's wholly owned subsidiary, PUR Biologics, is advancing its distribution network with a significant expansion in California.
Scientist, inventor, business expert, and holder of more than 140 patents will bring forward PUR Biologics' regenerative therapeutic patent portfolio to address unmet needs in the $200 billion osteoarthritis, pain, and cartilage & spinal disc regeneration markets. IRVINE CA / ACCESSWIRE / November 7, 2023 / HippoFi, Inc. (OTC PINK:ORHB) proudly announces the appointment of the world's foremost authority and pioneer of regenerative medicine, Gail Naughton, MBA, Ph.D, as the Company's "Head of Regenerative Therapeutics and Commercialization.
PUR Biologics' robust distribution channels prove to expand sales globally. IRVINE, CA / ACCESSWIRE / October 24, 2023 / Following a successful engagement at the North American Spine Society (NASS) conference, healthcare technology company, HippoFi, Inc. (OTC PINK:ORHB), announces its wholly owned subsidiary, PUR Biologics, has expanded its sales to include several notable international healthcare establishments.
IRVINE, CA / ACCESSWIRE / September 12, 2023 / Solidifying its role as a leader in medical advancements, PUR Biologics, a wholly-owned subsidiary of HippoFi (OTC PINK:ORHB), proudly announces its latest patent acquisition, further strengthening its reputation in the biotech sector. This patent is for a groundbreaking device designed to enhance the body's immune response, targeting advancements in pain relief, anti-cancer therapeutics, bone regeneration and other critical medical areas, tapping into large and lucrative markets.
IRVINE, CA / ACCESSWIRE / September 6, 2023 / HippoFi, Inc. (OTC PINK:ORHB) proudly announces a partnership with global medical technology leader ZIMMER BIOMET, aiming to redefine the spinal biologics landscape. This collaboration will harness the combined expertise of both companies to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi's biologic subsidiary, PUR Biologics.
IRVINE, CA / ACCESSWIRE / September 1, 2023 / HippoFi, Inc. (OTC PINK:ORHB) - HippoFi, in association with its wholly owned subsidiary PUR Biologics, is preparing to unveil the details of the closing of its strategic partnership and asset acquisition with a top 5 global leader in the orthopedic industry. This partnership requires a collaboration of distinct expertise and technology, aiming to shape the future landscape of spinal biologics.
No recent filings indexed.